| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/18/2000 | WO2000008057A3 Molecules designated b7l-1 |
| 05/18/2000 | WO2000007979A3 Compounds and compositions for delivering active agents |
| 05/18/2000 | WO2000002916B1 PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITY |
| 05/18/2000 | WO1999061467A3 Inhibition of the binding of protein tyrosine phosphatase pest to domains of signalling proteins |
| 05/18/2000 | WO1999052415A3 Therapeutics and diagnostics for congenital heart disease based on a novel human transcription factor |
| 05/18/2000 | WO1999024470A8 Mammalian milk growth factor |
| 05/18/2000 | DE19945814A1 Verfahren zur Zubereitung eines pharmazeutischen Artemisia-Extraktes und Vorrichtung zur elektrischen Moxibustion unter Verwendung des Extraktes A process for the preparation of a pharmaceutical Artemisia extract and moxibustion device for electrically using the extract |
| 05/18/2000 | DE19852729A1 Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung Recombinant glycoproteins, processes for their preparation, pharmaceutical compositions containing them and their use |
| 05/18/2000 | DE19850718C1 Zellpermeabilität-vermittelndes Polypeptid Cell permeability-mediating polypeptide |
| 05/18/2000 | CA2704598A1 Methods of purifying recombinant human erythropoietin from cell culture supernatants |
| 05/18/2000 | CA2355400A1 Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
| 05/18/2000 | CA2351167A1 Nucleic acids and polypeptides having altered expression in the t84 gut barrier model |
| 05/18/2000 | CA2351145A1 Vaccine against papillomatous digital dermatitis (pdd) |
| 05/18/2000 | CA2351063A1 A system for administering a bioactive agent by inhalation comprising a lipid mixture comprising phosphatidylcholine |
| 05/18/2000 | CA2351019A1 Htfiiia human gene and coded htfiiia protein |
| 05/18/2000 | CA2350915A1 Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof |
| 05/18/2000 | CA2350775A1 Chlamydia pneumoniae genome sequence |
| 05/18/2000 | CA2350771A1 Chemokine .beta.-7 |
| 05/18/2000 | CA2350388A1 Human hydrolase proteins |
| 05/18/2000 | CA2350183A1 Use of an enterobacterium protein ompa for specific targeting towards antigen-presenting cells |
| 05/18/2000 | CA2350182A1 Connective tissue growth factor (ctgf) and methods of use |
| 05/18/2000 | CA2350167A1 Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use |
| 05/18/2000 | CA2350133A1 A method for treating tissue damaged from ischemia |
| 05/18/2000 | CA2350087A1 Chromosome 17p-linked prostate cancer susceptibility gene |
| 05/18/2000 | CA2350058A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
| 05/18/2000 | CA2349951A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 05/18/2000 | CA2349815A1 Human cell surface receptor proteins |
| 05/18/2000 | CA2349814A1 Cytokine signal regulators |
| 05/18/2000 | CA2349761A1 Corticosteroid synthesis-associated genes |
| 05/18/2000 | CA2349720A1 Stimulation of angiogenesis via syndecan-4 cytoplasmic domain signaling pathway |
| 05/18/2000 | CA2349679A1 Modified exosomes and uses |
| 05/18/2000 | CA2349644A1 Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders |
| 05/18/2000 | CA2349592A1 Use of gm-csf to inhibit development of drug resistance in hiv+ patients |
| 05/18/2000 | CA2349498A1 Methods and compositions for treating or preventing peripheral neuropathies |
| 05/18/2000 | CA2349496A1 Delivery of superoxide dismutase to neuronal cells |
| 05/18/2000 | CA2349449A1 Cell surface glycoproteins |
| 05/18/2000 | CA2349445A1 Antisense oligomer |
| 05/18/2000 | CA2349159A1 Activity dependent neurotrophic factor iii (adnf iii) |
| 05/18/2000 | CA2348934A1 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 05/18/2000 | CA2348885A1 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 05/18/2000 | CA2348763A1 Novel compounds and medicinal use thereof |
| 05/18/2000 | CA2348699A1 Virulence genes and proteins, and their use |
| 05/18/2000 | CA2348382A1 Chimeric parvovirus vectors and methods of making and administering the same |
| 05/18/2000 | CA2348308A1 Rantes-derived peptides with anti-hiv activity |
| 05/18/2000 | CA2347916A1 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | CA2347847A1 A method of treating tumors using fas-induced apoptosis |
| 05/18/2000 | CA2317049A1 Topical compositions containing whey proteins |
| 05/17/2000 | EP1001033A2 Process for the valorization of starch into lactic acid-containing products, and obtained products |
| 05/17/2000 | EP1001032A2 Recombinant retroviruses delivering vector constructs to target cells |
| 05/17/2000 | EP1001030A1 Recombinant CELO virus and CELO virus DNA |
| 05/17/2000 | EP1001024A2 Protein encoded by the trkB proto-oncogene, used in assay systems for neurothophin activity |
| 05/17/2000 | EP1001023A2 Frizzled-4, a putative Wnt-receptor |
| 05/17/2000 | EP1001022A1 CAMEL, an alternative translation product of the tumour antigen LAGE-1 |
| 05/17/2000 | EP1000627A1 Aqueous preparation of lactoferrin having improved stability |
| 05/17/2000 | EP1000626A1 Chemokine receptor antagonist and cyclosporin in combined therapy |
| 05/17/2000 | EP1000357A1 Antibodies and scfv immunotoxins specific to imported fire ants, and their application |
| 05/17/2000 | EP1000167A2 Production of human mutant proteins in human cells by homologous recombination |
| 05/17/2000 | EP1000166A2 Inhibitors of cell-cycle progression and uses related thereto |
| 05/17/2000 | EP1000161A1 Anticoagulant fusion protein anchored to cell membrane |
| 05/17/2000 | EP1000158A1 Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders |
| 05/17/2000 | EP1000157A1 Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy |
| 05/17/2000 | EP1000155A1 Immunogenic fragments of toxin a of clostridium difficile |
| 05/17/2000 | EP1000154A1 Identification of human cell lines for the production of human proteins by endogenous gene activation |
| 05/17/2000 | EP1000153A2 Crustacean antimicrobial peptides |
| 05/17/2000 | EP1000152A2 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES |
| 05/17/2000 | EP1000149A2 5' ESTs FOR SECRETED PROTEINS IDENTIFIED FROM BRAIN TISSUES |
| 05/17/2000 | EP1000147A2 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN TESTIS AND OTHER TISSUES |
| 05/17/2000 | EP1000145A1 Heart and skeleton muscle specific nucleic acid, the production and use thereof |
| 05/17/2000 | EP1000144A2 Lactoferrin receptor genes of moraxella |
| 05/17/2000 | EP1000143A1 Frazzled nucleotide sequences, expression products, compositions and uses |
| 05/17/2000 | EP1000089A1 Collagen type i and type iii adhesive compositions |
| 05/17/2000 | EP1000087A2 Ancrod specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and use of the same |
| 05/17/2000 | EP1000086A1 Alatrofloxacin parenteral compositions |
| 05/17/2000 | EP1000085A1 Treatment of insulin resistance with growth hormone secretagogues |
| 05/17/2000 | EP1000084A1 123 human secreted proteins |
| 05/17/2000 | EP1000082A2 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 05/17/2000 | EP1000051A1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/17/2000 | EP0999851A1 Use of an enzyme for the manufacture of an agent for controlling bacterial infection |
| 05/17/2000 | EP0999850A2 Methods and compositions for regulating nuclear trafficking of proteins |
| 05/17/2000 | EP0999849A1 Therapeutic agent for the treatment of septicaemia, its preparation and use |
| 05/17/2000 | EP0999848A1 Chimeric proteins for the treatment of diabetes |
| 05/17/2000 | EP0999837A1 Treatment of diabetes with rosiglitazone and insulin |
| 05/17/2000 | EP0999825A1 Ophthalmic compositions containing galactomannan polymers and borate |
| 05/17/2000 | EP0841917A4 Method of treatment for exercise-induced pulmonary hemorrhage in racing stock |
| 05/17/2000 | EP0791011B1 Biologically active tgf-beta1 and tgf-beta2 peptides |
| 05/17/2000 | EP0773950A4 Linked peptide nucleic acids |
| 05/17/2000 | EP0726768B1 Use of nitric oxide releasing compounds for the manufacture of a medicament for protection in ischemia reperfusion injury |
| 05/17/2000 | EP0703922B1 Method for producing immunoglobulin g concentrate |
| 05/17/2000 | EP0632820B1 High concentration homogenized collagen compositions |
| 05/17/2000 | EP0620825B1 Heparin- and sulfatide-binding peptides from the type i repeats of human thrombospondin |
| 05/17/2000 | EP0601106B1 Morphogen-induced modulation of inflammatory response |
| 05/17/2000 | EP0574461B1 High affinity humanized monoclonal antibodies |
| 05/17/2000 | EP0553272B1 Synthetic lung surfactant |
| 05/17/2000 | CN1253589A Human complement C3-degrading proteinase from streptococcus pneumoniae |
| 05/17/2000 | CN1253588A Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants |
| 05/17/2000 | CN1253587A Methods and compositions for synthesis of long chain polyunsaturated fatty acids |
| 05/17/2000 | CN1253586A Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription actor interactions |
| 05/17/2000 | CN1253567A Cell surface molecule mediating cell adhesion and signal transmission |
| 05/17/2000 | CN1253566A Active substance and composition inhibiting tumorous proliferation in ectoderm derived tissues |
| 05/17/2000 | CN1253565A Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines |